Continued treatment of early virologic nonresponders or partial responders with bulevirtide monotherapy for chronic hepatitis delta leads to improvement in virologic and biochemical responses: Results from an integrated analysis at week 96

被引：0

作者：

Lampertico, Pietro ^{[1
,2
]}

Wedemeyer, Heiner ^{[5
]}

Brunetto, Maurizia ^{[3
,4
]}

Bogomolov, Pavel ^{[7
]}

Stepanova, Tatyana ^{[8
]}

Bourliere, Marc ^{[9
]}

Fontaine, Helene ^{[13
]}

Chee, Grace M. ^{[13
]}

Manuilov, Dmitry ^{[13
]}

An, Qi ^{[13
]}

Freismuth, Aurelie ^{[14
]}

Lau, Audrey ^{[13
]}

Da, Ben ^{[13
]}

Flaherty, John F. ^{[13
]}

Mercier, Renee-Claude ^{[13
]}

Frenette, Catherine ^{[13
]}

Osinusi, Anu ^{[13
]}

Gherlan, George Sebastian ^{[15
,16
]}

Streinu-Cercel, Adrian ^{[17
]}

Zeuzem, Stefan ^{[6
]}

Cornberg, Markus ^{[5
]}

Roulot, Dominique ^{[10
]}

Zoulim, Fabien ^{[11
]}

Aleman, Soo ^{[18
]}

Asselah, Tarik ^{[12
]}

机构：

[1] Fdn IRCCS Ca Granda Osped Maggiore Policlin, Div Gastroenterol & Hepatol, Milan, Italy

[2] Univ Milan, CRC AM & A Migliavacca Ctr Study Liver Dis, Milan, Italy

[3] Univ Hosp Pisa, Hepatol Unit, Reference Ctr Tuscany Reg Chron Liver Dis & Canc, Pisa, Italy

[4] Univ Pisa, Dept Clin & Expt Med, Pisa, Italy

[5] Hannover Med Sch, Clin Gastroenterol Hepatol Infect Dis & Endocrino, Hannover, Germany

[6] Univ Hosp Frankfurt, Frankfurt, Germany

[7] Moscow Reg Clin Res Inst, State Budgetary Inst Hlth Care Moscow Reg, Moscow, Russia

[8] LLC Clin Modern Med, Moscow, Russia

[9] Hop St Joseph, Marseille, France

[10] Univ Sorbonne Paris Nord, Bobigny, France

[11] Hosp Croix Rousee, Lyon, France

[12] Univ Paris, Hop Beaujon, Clichy, France

[13] Gilead Sci Pty Ltd, Foster City, CA USA

[14] Gilead Sci Pty Ltd, Melbourne, Australia

[15] Carol Davila Univ Med & Pharm, Bucharest, Romania

[16] Dr Victor Babes Fdn, Bucharest, Romania

[17] Matei Bals Natl Inst Infect Dis, Bucharest, Romania

[18] Karolinska Inst, Karolinska Univ Hosp, Stockholm, Sweden

来源：

JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY | 2024年 / 39卷

关键词：

D O I：

暂无

中图分类号：

R57 [消化系及腹部疾病];

学科分类号：

摘要：

278

引用

页码：102 / 103

页数：2

共 34 条

[21] Efficacy and safety of bulevirtide 2 mg or 10 mg monotherapy for chronic hepatitis delta at 96 weeks: Results from an interim analysis of a phase 3 randomized study
Wedemeyer, Heiner
Aleman, Soo
Brunetto, Maurizia
Blank, Antje
Andreone, Pietro
Bogomolov, Pavel
Chulanov, Vladimir
Mamonova, Nina
Geyvandova, Natalia
Morozov, Viacheslav
Sagalova, Olga
Stepanova, Tatyana
Manuilov, Dmitry
Mercier, Renee-Claude
An, Qi
Freismuth, Aurelie
Flaherty, John F.
Osinusi, Anu
Lau, Audrey
Wiesch, Julian Schulze Zur
Cornberg, Markus
Zeuzem, Stefan
Lampertico, Pietro
JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, 2024, 39 : 101 - 102
[22] HIGH RATES OF ADHERENCE TO BULEVIRTIDE MONOTHERAPY FOR CHRONIC HEPATITIS DELTA THROUGH 96 WEEKS: RESULTS FROM AN INTERIM ANALYSIS OF THE PHASE 3 STUDY MYR301
Aleman, Soo
Wedemeyer, Heiner
Brunetto, Maurizia R.
Blank, Antje
Andreone, Pietro
Bogomolov, Pavel
Chulanov, Vladimir
Mamonova, Nina
Geyvandova, Natalia
Morozov, Viacheslav
Sagalova, Olga
Stepanova, Tatyana V.
Da, Ben
Manuilov, Dmitry
Chee, Grace
Li, Mingyang
Lau, Audrey H.
zur Wiesch, Julian Schulze
Cornberg, Markus
Zeuzem, Stefan
Lampertico, Pietro
GASTROENTEROLOGY, 2024, 166 (05) : S1603 - S1604
[23] EFFICACY AND SAFETY AT 96 WEEKS OF BULEVIRTIDE 2 MG OR 10 MG MONOTHERAPY FOR CHRONIC HEPATITIS DELTA: RESULTS FROM AN INTERIM ANALYSIS OF A PHASE 3 RANDOMIZED STUDY
Wedemeyer, Heiner
Aleman, Soo
Brunetto, Maurizia
Blank, Antje
Andreone, Pietro
Bogomolov, Pavel
Chulanov, Vladimir
Mamonova, Nina
Geyvandova, Natalia
Morozov, Viacheslav
Sagalova, Olga
Stepanova, Tatyana
Manuilov, Dmitry
Mercier, Renee-Claude
An, Qi
Flaherty, John
Osinusi, Anu
Lau, Audrey
zur Wiesch, Julian Schulze
Cornberg, Markus
Zeuzem, Stefan
Lampertico, Pietro
GUT, 2023, 72 (SUPPL_3) : A103 - A104
[24] EFFICACY AND SAFETY AT 96 WEEKS OF BULEVIRTIDE 2 MG OR 10 MG MONOTHERAPY FOR CHRONIC HEPATITIS DELTA: RESULTS FROM AN INTERIM ANALYSIS OF A PHASE 3 RANDOMIZED STUDY
Wedemeyer, Heiner
Aleman, Soo
Brunetto, Maurizia R.
Blank, Antje
Andreone, Pietro
Bogomolov, Pavel
Chulanov, Vladimir
Mamonova, Nina
Geyvandova, Natalia
Morozov, Viacheslav
Sagalova, Olga
Stepanova, Tatyana V.
Manuilov, Dmitry
Mercier, Renee-Claude
An, Qi
Flaherty, John F.
Osinusi, Anu
Lau, Audrey H.
Wiesch, Julian Schulze zur
Cornberg, Markus
Zeuzem, Stefan
Lampertico, Pietro
GASTROENTEROLOGY, 2024, 166 (05) : S1600 - S1600
[25] EFFICACY AND SAFETY AT 96 WEEKS OF BULEVIRTIDE 2 MG OR 10 MG MONOTHERAPY FOR CHRONIC HEPATITIS DELTA: RESULTS FROM AN INTERIM ANALYSIS OF A PHASE 3 RANDOMIZED STUDY
Wedemeyer, Heiner
Aleman, Soo
Brunetto, Maurizia
Blank, Antje
Andreone, Pietro
Bogomolov, Pavel
Chulanov, Vladimir
Mamonova, Nina
Geyvandova, Natalia
Morozov, Viacheslav
Sagalova, Olga
Stepanova, Tatyana
Manuilov, Dmitry
Mercier, Renee-Claude
An, Qi
Flaherty, John
Osinusi, Anu
Lau, Audrey
zur Wiesch, Julian Schulze
Cornberg, Markus
Zeuzem, Stefan
Lampertico, Pietro
GUT, 2023, 72 : A103 - A104
[26] Entecavir (ETV) treatment through 96 weeks results in substantial virologic and biochemical improvement and HBeAg seroconversion in HBeAg(+) chronic hepatitis B (CHB) patients (study ETV-022)
Sollano, J.
De Man, R. A.
Mutimer, D.
Gish, R. G.
Chang, T. -T.
Zhu, J.
Cross, A.
Brett-Smith, H.
LIVER INTERNATIONAL, 2006, 26 : 6 - 7
[27] Entecavir (ETV) treatment through 96 weeks results in substantial virologic and biochemical improvement and HBeAg seroconversion in HBeAg(+) chronic hepatitis B (CHB) patients (study ETV-022)
Chang, Ting-Tsung
Chao, You-Chen
Sollano, Jose
Han, Kwang-Hyub
Lai, Ching-Lung
Lao-Tan, Judy
Akbar, Nurul
Zhu, Jin
Cross, Anne
Brett-Smith, Helena
Neo, Boon-Leong
JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, 2006, 21 : A33 - A33
[28] Entecavir (ETV) treatment through 96 weeks results in substantial virologic and biochemical improvement and HBeAg seroconversion in HBeAg(+) chronic hepatitis B (CHB) patients (study ETV-022)
Chang, Ting-Tsung
Chao, You-Chen
Sollano, Jose
Han, Kwang-Hyub
Lai, Ching-Lung
Lao-Tan, Judy
Akbar, Nurul
Zhu, Jin
Cross, Anne
Brett-Smith, Helena
Neo, Boon-Leong
JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, 2006, 21 : A89 - A89
[29] Entecavir (ETV) treatment through 96 weeks results in substantial virologic and biochemical improvement and HBeAg seroconversion in HBeAg(+) chronic hepatitis B (CHB) patients (study ETV-022)
De Man, R. A.
Mutimer, D.
Gish, R.
Chang, T.
Zhu, J.
Cross, A.
Brett-Smith, H.
JOURNAL OF CLINICAL VIROLOGY, 2006, 36 : S89 - S89
[30] Integrated safety analysis of 24-week data from three phase 2 and one phase 3 clinical trials of bulevirtide monotherapy given at 2 mg and 10 mg dose level for treatment of chronic hepatitis delta
Lampertico, Pietro
Aleman, Soo
Asselah, Tarik
Bourliere, Marc
Streinu-Cercel, Adrian
Bogomolov, Pavel
Viacheslav, Morozov
Stepanova, Tatyana
Lazar, Stefan
Suri, Vithika
Manuilov, Dmitry
Ye, Lei
Flaherty, John F.
Osinusi, Anu
Brunetto, Maurizia
Wedemeyer, Heiner
JOURNAL OF HEPATOLOGY, 2022, 77 : S829 - S829

← 1 2 3 4 →